Biopharmaceuticals are complex medicines that are manufactured by extracting proteins and nucleic acids directly from biological sources using biotechnology. Most biopharmaceuticals are pharmaceutical products that are made from living organisms; transgenic organisms are genetically modified plants and animals, and this process is used to produce biopharmaceuticals; nevertheless, it is a controversial technology still in the testing phase. The market demand for biopharmaceuticals is due to rising application in cancer therapeutics and potential to treat rare diseases are the most important factor driving the growth of this market. Additionally, the ability of biopharmaceuticals to address untreatable conditions is also expected to accelerate the market’s overall growth. Additionally, the expanding global healthcare sector and increasing awareness of the efficacy and availability of biopharmaceuticals among the population are expected to cushion the market’s growth over the forecast period.
Eli Lilly and Co and Amgen Inc – Notable Market Players in Biopharmaceuticals Market
Market leaders operating in the market have undertaken various organic growth strategies in the biopharmaceuticals market. the biopharmaceuticals market majorly consists of the players Amgen Inc, AbbVie Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, Johnson & Johnson, Thermo Fisher Scientific Inc, AGC Biologics AS, Lonza Group AG, WuXi Biologics Inc, and Boehringer Ingelheim International GmbH among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals.
Below is the list of organic growth strategies done by the players operating in the biopharmaceuticals market:
|
Company |
Month & Year |
Category |
Description |
|
Lonza Group AG |
Oct-2022 |
Company News |
Lonza announced that two additional cell and gene therapies manufactured at its Houston (US) site had reached commercial approval in Q3 2022. ZYNTEGLO is used for treating transfusion-dependent beta-thalassemia and SKYSONA, for treating early, active cerebral adrenoleukodystrophy, are manufactured by bluebird bio of Somerville, Massachusetts, and were approved in August and September, respectively. These regulatory approvals represent the second and third cell and gene therapy commercial approvals supported by Lonza’s Houston (US) facility. |
|
Eli Lilly and Co |
Jun-2022 |
Product News |
Eli Lilly and Company modified the purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately US$ 275 million. Bebtelovimab continues to maintain neutralization activity against the most common, and fastest growing, Omicron variants in the United States, in addition to all known variants of interest and concern. |
|
Apr-2022 |
Product Approval |
Bristol Myers Squibb Opdivo (nivolumab) was approved by the European Commission (EC) in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with esophageal squamous cell carcinoma (ESCC) in the 27-member states of the European Union, as well as Iceland, Liechtenstein, and Norway |
|
|
Johnson & Johnson |
Mar-2022 |
Expansion |
Johnson & Johnson subsidiary, Janssen Sciences Ireland, expanded its biopharmaceutical supply chain facility in Ringaskiddy, Co. Cork. The US$ 196.96m (€150m) investment in the facility can potentially create 180 full-time jobs. The expansion benefits the existing global manufacturing capacity, allowing the company to reach patients with crucial biomedicines faster. |
|
Amgen Inc |
Mar-2022 |
Expansion |
Amgen announced the groundbreaking of its new biomanufacturing facility, located in Holly Springs, NC, that is expected to be operational by 2025. The facility will support the growing demand for medicines that treat serious illnesses such as cancer and heart disease. The new facility will produce a wide range of medicines, utilizing new technologies to maximize efficiency and quality |
|
Eli Lilly and Co |
Feb-2022 |
Product News |
Eli Lilly and Company announced that the U.S. FDA issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant. |
|
Eli Lilly and Co |
Dec-2021 |
Product News |
Eli Lilly and Company announced that the U.S. FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to <12 years old. This expansion allows for bamlanivimab and etesevimab to be administered together in high-risk pediatric patients for treating mild to moderate COVID-19 as well as post-exposure prophylaxis |
|
Eli Lilly and Co |
Nov-2021 |
Product News |
Eli Lilly and Company announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. The neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals. As part of the agreement, Lilly supplied 614,000 doses of bamlanivimab with for a total of US$1.29 billion. |
|
Boehringer Ingelheim International GmbH |
Oct-2021 |
Expansion |
Boehringer Ingelheim inaugurated its state-of-the-art biopharmaceutical production facility Large Scale Cell Culture (LSCC) in Vienna, Austria. With an investment volume of over US$ 737.96 million (EUR 700 million), being the largest investment in the company’s history. The facility is one of the most advanced of its kind, ensuring a high degree of digitalization and automation through smart technologies and artificial intelligence applications. The new facility is an essential addition to the company’s global biopharmaceutical network and underlines the strong commitment of Boehringer Ingelheim to Europe. |
|
Boehringer Ingelheim International GmbH |
Oct-2021 |
Company News |
Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh), and Oxford Biomedica (OXB), announced that Boehringer Ingelheim had exercised their options on intellectual property and know-how from the partners to progress and further accelerate the development of a potential, new treatment option for patients with cystic fibrosis (CF). In the partnership, IP Group, acting on behalf of the three GTC host Universities, granted exclusive global rights to develop, manufacture, register, and commercialize the lentiviral vector-based gene therapy for treating cystic fibrosis. |
|
Johnson & Johnson |
Sep-2021 |
Product News |
Johnson & Johnson’s Ebola vaccine regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) data from two papers published in The Lancet Infectious Diseases showed that it generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. |
|
AGC Biologics AS |
Jun-2021 |
Expansion |
AGC Biologics, a leading global CDMO, partnered with BioNTech SE to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at AGC’s Heidelberg, Germany facility. AGC Biologics manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine manufacturing process. |
|
Amgen Inc |
Apr-2021 |
Product News |
Amgen was granted the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (GEJ) adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin). Following sotorasib, bemarituzumab is the second asset in Amgen’s oncology portfolio to receive Breakthrough Therapy Designation. |
|
AGC Biologics AS |
Mar-2021 |
Expansion |
AGC Biologics, a biopharmaceutical CDMO subsidiary of AGC Inc decided to expand the capacity for gene and cell therapy. At the Milan site Bresso Plant, the company installs new viral vector production equipment and enhance its analytics and process development facilities. The new facilities are scheduled to begin full operation in 2022. |
|
AGC Biologics AS |
Nov-2020 |
Expansion |
AGC Biologics focuses on increasing the production capacity of its Copenhagen facility that is an important part of its global expansion plan. It constructs a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors, labs, and office space. The new building will have a total floor area of approximately 19,000m2. The total investment for the expansion was approximately US$ 189.31M (€160M), and the start of operation is scheduled for 2023. |
|
Johnson & Johnson |
Jul-2020 |
Product Approval |
Johnson & Johnson received marketing authorization from European Commission (EC) for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen to prevent Ebola Virus Disease. Two Marketing Authorisation Applications (MAAs) were submitted to the European Medicines Agency (EMA) for the vaccines composing the two-dose regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Enabled by the approval, Janssen collaborated with the World Health Organization (WHO) on vaccine pre-qualification, which helped to accelerate registration of its preventive Ebola vaccine regimen in African countries and facilitate broader access to those most in need. |
